A critical analysis of a UCLA-led pilot study on estriol hormone therapy for menopause-related brain fog, detailing evidence, limitations, and executive impact.
In August 2026, a UCLA Health research team published an observational case series in Scientific Reports. The study examined whether a customized hormone regimen containing estriol and progesterone could improve menopause-related cognitive symptoms. This research evaluated a specific treatment patented by UCLA and licensed to a company called CleopatraRX. The resulting product is marketed under the name PearlPAK.
Cognitive symptoms during menopause are often minimized in clinical settings. Many women are told to tolerate memory lapses and slower processing speeds. The UCLA study focused directly on these cognitive complaints rather than treating them as a secondary issue. The researchers sought to determine if a targeted hormone approach could offer measurable relief.
The UCLA Health research team followed 20 menopausal women through a structured treatment protocol. The participants had an average age of 53 at the start of the clinical tracking. Researchers conducted a baseline cognitive assessment before initiating the customized estriol and progesterone therapy. The clinical monitoring continued for a total of 12 months.
Estriol is a naturally occurring form of estrogen that is produced primarily during pregnancy. It differs significantly from estradiol, which is the most commonly used estrogen hormone therapy in the United States. Estriol primarily targets a different estrogen receptor in the brain. While it is used in Europe and Asia for hot flashes, it is not approved by the U.S. Food and Drug Administration.
After one year of treatment, the participants reported significant improvements across several symptom categories. These areas included concentration, working memory, processing speed, and verbal memory. The subjects also noted better problem-solving abilities and a reduction in their overall perception of cognitive fog. The study paired these human observations with complementary experiments in midlife female mice.
The animal component of the research supported a biological hypothesis involving the hippocampus. The hippocampus is a brain region strictly associated with learning and memory formation. Following estriol treatment, the mice showed less deterioration in this critical neurological region. They also demonstrated better performance on specific spatial-memory and working-memory tasks.
Dr. Rhonda Voskuhl is a neurologist at UCLA Health and the senior author of the study. She noted that estrogen plays a well-documented role in protecting the brain. Voskuhl highlighted that there are still no approved treatment types specifically targeting menopause cognitive symptoms. She cited this clinical care gap as a primary motivation for investigating the estriol regimen.
Memory lapses and reduced concentration create severe operational friction for organizational leaders. Subjective brain fog directly impacts decision quality, meeting follow-through, and strategic execution. ExecuFuel focuses on the realities of Executive Performance, where consistent cognitive clarity is an absolute requirement. This study offers a signal worth testing but not a proven performance enhancement prescription.
Ambitious professionals must separate the presence of symptoms from the validation of specific treatments. An executive experiencing new concentration problems should always begin with a comprehensive clinical assessment. Assuming every memory lapse is caused by menopause can mask other highly treatable medical conditions. Sleep disruption, mood symptoms, thyroid disease, and medication effects can all degrade daily cognitive performance.
Founders and investors operate in environments that demand constant mental agility. When brain fog compromises this agility, the resulting stress often compounds the initial cognitive friction. Addressing these symptoms methodically is crucial for maintaining long-term organizational health and personal stamina. Relying on verified clinical evaluations ensures that leaders address the root cause of their fatigue.
If an individual pursues treatment under medical supervision, they should track outcomes prospectively. Useful tracking measures include perceived brain fog, sleep quality, and the frequency of vasomotor symptoms. Leaders can also monitor meeting follow-through and the efficiency of daily task switching. Personal tracking provides practical feedback but is never a substitute for a controlled clinical trial.
Leadership teams can also respond to these challenges without medicalizing performance problems. Organizations can provide flexible scheduling and actively reduce avoidable context switching during the workday. Improved meeting documentation and confidential access to specialized healthcare also support sustained professional performance. These operational adjustments help preserve output while clinicians determine the appropriate medical plan.
The human trial centered entirely on 12 months of customized hormone administration. The 20 participants completed self-reported assessments of their cognitive efficiency throughout the study period. According to HealthDay reports, the subjects experienced clear relief from subjective brain fog. However, the available summaries do not provide the exact numerical change or confidence intervals for each domain.
The lack of standardized effect sizes means the absolute magnitude of the improvement remains unclear. Self-reported symptom relief is highly meaningful for the individual patient experiencing cognitive friction. However, self-reported data should never be presented as proof of objective intelligence gains. True improvements in workplace productivity and measurable executive functioning require distinct validation methods.
ExecuFuel strictly prioritizes intellectual honesty when analyzing early clinical data. UCLA explicitly described the human research as an observational case series. The study was not a randomized controlled trial. Findings from a small group of just 20 participants remain vulnerable to random statistical variation.
The absence of a control group is a significant structural limitation in this research. Without a placebo group, researchers cannot reliably separate treatment effects from natural symptom fluctuation. The reported improvements could simply reflect better sleep or relief from hot flashes. They might also stem from expectancy effects occurring over the 12 months of clinical observation.
The study also carries a material conflict of interest disclosure that requires careful attention. UCLA owns the patent for the specific treatment and licenses it to CleopatraRX. Dr. Voskuhl serves as a medical adviser to the company marketing the product as PearlPAK. While this disclosure does not invalidate the findings, it drastically increases the need for independent replication.
Furthermore, professionals must avoid using cognitive symptoms to justify pursuing unregulated products. Estriol is available in the United States only as a compounded medication. This status creates important questions about regulatory oversight, product consistency, and standardized prescribing guidelines. Evidence from one customized regimen does not necessarily apply to other available compounded formulations.
Finally, this treatment must not be viewed as a reliable dementia prevention strategy. Current clinical guidance does not support using menopausal hormone therapy to prevent dementia. U.S. estrogen product labeling clearly warns against using estrogen-alone therapy for this purpose. Relief from temporary brain fog is completely distinct from preventing long-term Alzheimer’s disease.
The research team emphasized that their initial results are early and highly preliminary. They stated that larger placebo-controlled studies are necessary to determine if the findings can be replicated. Future trials must incorporate advanced brain imaging and standardized cognitive testing. This rigorous approach is the only way to establish true clinical efficacy and objective performance gains.
Broader evidence regarding hormone therapy shows that results vary significantly based on individual factors. Current data indicates that timing, formulation, and duration of therapy dictate the cognitive trajectory. Short-term therapy initiated near menopause shows different outcomes compared to long-duration regimens started later. These nuances underscore why precision medicine is essential for Healthy Aging & Executive Longevity.
The strongest near-term takeaway is that menopause-related cognitive symptoms deserve serious medical attention. Women no longer have to accept diminished processing speed as an inevitable reality of professional aging. However, any intervention must rely on individualized medical care tailored to specific health histories. Executives should consult qualified clinicians rather than attempting to self-treat complex hormonal changes.
The industry is slowly shifting toward a more comprehensive view of Cognitive Performance & Mental Clarity. We will continue monitoring the independent replication of these estriol findings closely. Advancements in targeted therapies will eventually provide a more stable foundation for preserving leadership cognition. Until those larger trials conclude, the current standard of care remains careful clinical evaluation and individualized medical guidance.
Stay connected for research and practical guidance on executive performance, energy, focus, sleep, recovery and longevity. Ideas built for people who want to stay sharp, capable and effective for the long run.
Build habits and systems that support clear thinking, steady energy and long term capacity throughout a demanding career.
explore the Blog
